PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 1, 1998Diabetes Care81 citationsOpen Access

Safety and feasibility of dobutamine-atropine stress echocardiography for the diagnosis of coronary artery disease in diabetic patients unable to perform an exercise stress test.

AEAbdou ElhendyRDRon T. van DomburgDPDon Poldermans

Structured PICO

Does dobutamine-atropine stress echocardiography have comparable safety, feasibility, and diagnostic accuracy in diabetic versus nondiabetic patients with limited exercise capacity?

P
Population
1,446 consecutive patients (aged 60+/-12 years, 962 men) with limited exercise capacity and suspected myocardial ischemia, including 184 patients with IDDM or NIDDM.
I
Intervention
Dobutamine (up to 40 microg/kg/min) and atropine (up to 1 mg) stress echocardiography in diabetic patients.
C
Comparator
Nondiabetic patients undergoing the same dobutamine-atropine stress echocardiography protocol.
O
Outcome
Safety (occurrence of myocardial infarction, death, hypotension, ventricular tachycardia, supraventricular tachycardia) and feasibility (achievement of 85% of maximal heart rate and/or an ischemic end point).safety

Dobutamine-atropine stress echocardiography is a safe, feasible, and accurate diagnostic modality for coronary artery disease in diabetic patients who cannot perform exercise stress testing.

Abstract

OBJECTIVE: Dobutamine stress testing is increasingly used for the diagnosis and functional evaluation of coronary artery disease. However, little is known about the safety and feasibility of this stress modality in diabetic patients. RESEARCH DESIGN AND METHODS: We studied the impact of diabetes on hemodynamic profile and on the safety and feasibility of dobutamine (up to 40 microg x kg(-1) x min(-1)) and atropine (up to 1 mg) stress echocardiography for the diagnosis of coronary artery disease in 1,446 consecutive patients (aged 60+/-12 years, 962 men) with limited exercise capacity and suspected myocardial ischemia. Of these, 184 patients were known to have IDDM or NIDDM. The test was considered feasible when 85% of the maximal heart rate and/or an ischemic end point (new or worsened wall motion abnormalities, ST segment depression, or angina) was achieved. RESULTS: No myocardial infarction or death occurred during the test. There was no significant difference between diabetic and nondiabetic patients with regard to heart rate increase during dobutamine stress echocardiography (58+/-25 vs. 61+/-24 beats/min), peak rate pressure product (18,400+/-3,135 vs. 18,048+/-4454), or the prevalence of hypotension (systolic blood pressure drop of >40 mmHg) (7 vs. 5%), ventricular tachycardia (5.4 vs. 4.5%), and supraventricular tachycardia (3 vs. 4%) during the test. Dobutamine stress echocardiography was feasible in 92% of the diabetic patients and in 90% of the nondiabetic patients. Coronary angiography was performed in 55 diabetic and 240 nondiabetic patients. Sensitivity, specificity, and accuracy of dobutamine stress echocardiography for the diagnosis of coronary artery disease in diabetic patients were 81, 85, and 82%. Those in nondiabetic patients were 74, 87, and 77%, respectively (NS). CONCLUSIONS: Dobutamine stress echocardiography is a feasible method for the diagnosis of coronary artery disease in patients with limited exercise capacity with a comparable safety, feasibility, and accuracy in diabetic and nondiabetic patients.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Elhendy et al. (1998) studied this question.

synapsesocial.com/papers/6a742e534507312cc5a7f6b3https://doi.org/10.2337/diacare.21.11.1797
Ask AI
Helpful
Bookmark
Share
View Full Paper